Hormonal
Tirzepatide significantly increases the odds of achieving clinically meaningful weight loss (≥10% body weight reduction) compared to semaglutide.
A key benefit of tirzepatide over semaglutide is the increased likelihood of losing 10% or more of your body weight, a threshold often associated with significant health improvements. This makes tirzepatide a potentially more effective option if your primary goal is substantial weight reduction. Discuss with your provider whether this higher efficacy profile aligns with your health goals.
participants receiving tirzepatide had significantly higher odds of achieving at least 10% weight loss compared to those receiving semaglutide (OR: 0.21, 95% CI: 0.06 to 0.78).
Why this rating
Based on pooled analysis of 3 studies included in this specific metric, with high heterogeneity.
Source
Tirzepatide Versus Semaglutide for Weight Loss in Overweight and Obese Adults: A Systematic Review and Meta-Analysis of Direct Comparative Studies
Nazish Munawar et al. · Cureus · 2025
DOI 10.7759/cureus.86080
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →